FDA Osteporosis Drug Warning Contrasts Pior Advisory

Physician's First Watch reports that that "FDA Says Bisphosphonates Might Increase Femoral Fracture Risk, Orders Label Change". The FDA indicated that the reported fractures "may be related to use of bisphosphonates for longer than five years." Consequently, physicians are advised to reevaluate the need for the drugs if their patients have been using them longer than five years.

The FDA recent FDA advisory on the popular oseteoporisis medication known as bisphosphonates is in contrast the the earlier reassurance that there was no “clear connection” between use of bisphosphonates and atypical femoral fractures. The changes to the warnings section of all bisphosphonates given for osteoporosis will highlight the potential risk for subtrochanteric and diaphyseal femoral fractures. In addition, manufacturers will be required to include a medication guide for use by patients.